Header Logo

Connection

Dusan Stefoski to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Dusan Stefoski has written about Drug Administration Schedule.
Dusan Stefoski
Connection Strength
0.026
Drug Administration Schedule
  1. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.